A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate participant-reported preference for either ibandronate or a
comparator drug in women with postmenopausal osteoporosis. The anticipated time of study
treatment is 6 months, and the target sample size is 338 individuals.